- Home
- ARHS vs SANA Comparison
ARHS vs SANA Comparison
Compare ARHS & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | SANA |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ARHS | SANA |
|---|---|---|
| Price | $9.71 | $3.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $12.00 | $7.83 |
| AVG Volume (30 Days) | 958.6K | ★ 2.5M |
| Earning Date | 02-26-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $1,361,388,000.00 | N/A |
| Revenue This Year | $9.59 | N/A |
| Revenue Next Year | $6.46 | N/A |
| P/E Ratio | $20.52 | ★ N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $6.61 | $1.26 |
| 52 Week High | $12.98 | $6.55 |
Technical Indicators
Market Signals| Indicator | ARHS | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 38.60 | 39.89 |
| Support Level | $10.54 | $3.53 |
| Resistance Level | $11.23 | $4.10 |
| Average True Range (ATR) | 0.51 | 0.32 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 7.67 | 20.06 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.